Pictet Asset Management SA trimmed its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) by 39.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 744,725 shares of the company’s stock after selling 483,247 shares during the period. Pictet Asset Management SA owned approximately 1.31% of Ventyx Biosciences worth $24,948,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of VTYX. Legal & General Group Plc boosted its position in shares of Ventyx Biosciences by 152.3% during the 2nd quarter. Legal & General Group Plc now owns 2,422 shares of the company’s stock worth $30,000 after purchasing an additional 1,462 shares in the last quarter. UBS Group AG purchased a new stake in shares of Ventyx Biosciences during the 4th quarter worth $40,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Ventyx Biosciences during the 4th quarter worth $67,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Ventyx Biosciences by 27.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,593 shares of the company’s stock worth $87,000 after purchasing an additional 561 shares in the last quarter. Finally, American International Group Inc. boosted its position in shares of Ventyx Biosciences by 102.3% during the 2nd quarter. American International Group Inc. now owns 10,490 shares of the company’s stock worth $128,000 after purchasing an additional 5,305 shares in the last quarter.
Insider Activity at Ventyx Biosciences
In related news, insider William J. Sandborn sold 10,790 shares of the business’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $32.70, for a total value of $352,833.00. Following the completion of the transaction, the insider now owns 48,389 shares of the company’s stock, valued at approximately $1,582,320.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider William J. Sandborn sold 10,790 shares of the business’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $32.70, for a total value of $352,833.00. Following the completion of the transaction, the insider now owns 48,389 shares of the company’s stock, valued at approximately $1,582,320.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Raju Mohan sold 30,000 shares of the company’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $34.36, for a total transaction of $1,030,800.00. Following the transaction, the chief executive officer now directly owns 1,513,126 shares of the company’s stock, valued at approximately $51,991,009.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 598,715 shares of company stock valued at $21,766,008. 24.39% of the stock is owned by insiders.
Ventyx Biosciences Stock Up 4.0 %
Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) last announced its earnings results on Thursday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.20). During the same quarter in the previous year, the business earned ($0.39) EPS. As a group, research analysts predict that Ventyx Biosciences, Inc. will post -3.3 EPS for the current year.
Analyst Upgrades and Downgrades
VTYX has been the topic of several research analyst reports. Oppenheimer decreased their target price on shares of Ventyx Biosciences from $62.00 to $57.00 in a research report on Friday, August 11th. 500.com restated a “reiterates” rating on shares of Ventyx Biosciences in a research report on Friday, May 12th. Credit Suisse Group cut their price target on Ventyx Biosciences from $63.00 to $62.00 and set an “outperform” rating for the company in a research note on Friday, August 11th. Finally, HC Wainwright cut their price target on Ventyx Biosciences from $54.00 to $52.00 and set a “buy” rating for the company in a research note on Friday, August 11th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $57.22.
Get Our Latest Research Report on VTYX
About Ventyx Biosciences
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Featured Stories
- Five stocks we like better than Ventyx Biosciences
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- MarketBeat Week in Review – 8/14 – 8/18
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 8 Best Artificial Intelligence Stocks Under $10
- Space Investment: How to Invest in Space Exploration
- What Ross Stores Earnings Say About The Saver Shopping Economy
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
